Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for:<\/p>\n
Ipilimumab was approved by the U.S. Food and Drug Administration (FDA) in March 2011, to treat people with late-stage melanoma that has spread or cannot be removed by surgery.<\/p>\n
Yervoy (Ipilimumab Injection) for intravenous use Initial U.S. Approval: 2011
\nTo access Ipilimumab Injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n","protected":false},"excerpt":{"rendered":"
Yervoy (ipilimumab) is a kinase inhibitor indicated for the treatment of\u00a0\u00a0advanced (unresectable or metastatic) melanoma.<\/p>\n
API: ipilimumab If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cIpilimumab Injection\u201d based on the information you provide.<\/strong><\/p>\n
\nTrade Name: On Request
\nPackaging: injection, for intravenous use
\nStrength: Injection: 50 mg\/10 mL (5 mg\/mL) and 200 mg\/40 mL (5 mg\/mL) in a single-use vial.
\nDISEASE INDICATIONS-Urothelial Carcinoma, Skin Cancer
\nMANUFACTURER-Bristol-Myers Squibb
\nUSAGE-Intravenous
\nMEDICINE APPROVED BY-European Medical Agency (EMA), Food and Drug Administration (FDA), Pharmaceuticals and Medical Devices Agency (PMDA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n